Analisis Laporan Keuangan Untuk Mengukur Kinerja Pada Kpri “Satu” Di Boyolali

Tujuan penelitian ini adalah untuk mengetahui kinerja keuangan jika diukur berdasarkan analisis laporan keuangan menggunakan metode rasio keuangan (rasiolikuiditas, rasiosolvabilitas, dan rasio profitabilitas). Penelitian ini menggunakan data sekunder yang berasal dari laporan keuangan KPRI SATU dokumen yang di arsipkan oleh Kantor Dinas Koperasidan UMKM Kabupaten Boyolali. Berdasarkan hasil dari penelitian diketahui bahwa Current ratio tahun 2009 sebesar 230,4, current ratio tahun 2010 meningkat menjadi 238,5, current ratio tahun 2011 meningkat menjadi 251,4, current ratio tahun 2012 meninkat menjadi 264,3 dan current ratio tahun 2013 meningkat menjadi 272,8 artinya setiap satu rupiah hutang lancar yang dimilikinya dijamin dengan total aktiva lancar. Quick ratio tahun 2009 sebesar 2,261%, tahun 2010 naik sebesar 2,341%, tahun 2011 naik sebesar 2,471%, tahun,tahun 2012 naik sebesar 2,599%, tahun 2013 naik sebesar 2,682% yang berarti KRI “Satu” di Boyolali dapat menjamin setiap satu rupiah total hutang lancer dengan aktiva lancar-persediaan. Solvability di atas solvability tahun 2009 diperoleh hasil sebesar 45,60, pada tahun 2010 meningkat sebesar 44,65%, pada tahun 2011 sebesar 42,74%, pada tahun 2012 sebesar 40,88% sedangkan pada tahun 2013 sebesar 39,81%. Hal ini berarti KPRI “Satu” Boyolali mengalami penurunan laba untuk setiap tahunnya. Net profit margin tahun 2009 sebesar 82,05 pada tahun 2010 net profit margin meningkat menjadi 11,14, pada tahun 2011 net profit margin menurun menjadi 8,85, pada tahun 2012 net profit margin meningkat menjadi 11,50 dan pada tahun 2013 net profit margin meningkat menjadi 11,57. Hal ini berarti tahun 2009 sampai tahun 2010 mengalami peningkatan dibandingkan dengan tahun 2011 menurun dan pada tahun 2012 sampai tahun 2013 meningkat berarti Koperasi Pegawai Republik Indonesia ”Satu” di Boyolali mampu menghasilkan laba. Return on Asset tahun 2009 diperoleh hasil sebesar 13,06, Return on Asset tahun 2010 diperoleh hasil sebesar 8,24, Return on Asset tahun 2011 diperoleh hasil sebesar 6,16, Return on Asset tahun 2012 diperoleh hasil sebesar 7,78, dan Return on Asset tahun 2013 diperoleh hasil sebesar 7,72. Return on Equity di atas Return on Asset tahun 2009 diperoleh hasil sebesar 24,0, Return on Asset tahun 2010 diperoleh hasil sebesar 1,49, Return on Asset tahun 2011 diperoleh hasil sebesar 1,06, Return on Asset tahun 2012 diperoleh hasil sebesar 1,32, dan Return on Asset tahun 2013 diperoleh hasil sebesar 1,2

Ultrasonic time of flight estimation for wind speed measurement based on time-frequency domain using STFT

Peer Reviewe

Contribution of polymorphisms in IFNG and TNF to complications of the allogeneic hematopoietic stem cell transplantation with sibling donors

Las complicaciones del trasplante alogénico de células progenitoras hematopoyéticas (TACPH) relacionado incluyen tiempos variables de engraftment,enfermedad injerto contra huésped (EICH), infeccionesbacterianas y reactivación de citomegalovirus(CMV), entre otras. La existencia de polimorfismosen genes no HLA que codifican citoquinas proinflamatoriastales como el factor de necrosis tumoralalfa (TNF) e interferón gamma (IFNG) condicionaría la aparición de estas complicaciones. Se evaluóel impacto de la variante +1349 CAn del gen INFG y del polimorfismo -308 G/A de TNF en el engraftment y en la EICH en 148 receptores de TACPHrealizados en los centros participantes. Con respecto al engraftment tardío (≥15 días), el análisis multivariado confirmó el poder predictivo desfavorable del genotipo CAno12/no12 (baja producción) de IFNG(OR 3,9; p=0,003), médula ósea (MO) como fuente de células progenitoras (OR 4,6; p=0,013) y bacteriemia (OR 3,0; p=0,033). En relación a EICHa 3-4,las variables independientes fueron el genotipo de baja producción de IFNG (OR 0,1; p=0,008), bacteriemia (OR 3,3; p=0,048) y presencia de CMV(OR3,3; p=0,046). Y con respecto a EICHc, el riesgo fue influenciado por el genotipo -308 GG (producción baja) de TNF (OR 3,3; p=0,038), SP como fuente (OR 5,0; p=0,028), acondicionamiento mieloablativo (OR 3,3; p=0,014) y antecedente de EICHa 2-4 (OR 2,6; p=0,029). Aunque es necesario confirmar estos hallazgos, el genotipo de baja producción de IFNG se asoció con engraftment tardío y menor EICHa, mientras que los genotipos de baja producción de TNF se relacionaron con mayor incidencia de EICHc. Las variantes polimórficas estudiadas contribuirían al desarrollo de complicaciones en pacientes con TACPH relacionado.Complications of allogeneic hematopoietic stem cell transplantation (allo-HSCT) include variable engraftment times, acute (aGVHD) and chronic (cGVHD) graft-versus-host diseases, bacterial infections and reactivation of cytomegalovirus (CMV), among others. The existence of polymorphisms in non-HLA genes that encode pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF) and interferon gamma (IFNG) would condition the appearance of these complications. The impact of polymorphic variants +1349 CAn of INFG gene and -308 G/A of TNF was evaluated on the engraftment and GVHD in 148 allo-HSCT recipients with sibling donors. In the multivariate analysis, the genotype CAno12/no12 (low production) of INFG (OR 3.9, p=0.003), bone marrow (BM) as source of progenitor cells (OR 4.6, p=0.013) and bacteremia (OR 3.0, p=0.033) maintained their predictive power with respect to late engraftment (≥15 days). Genotype of low IFNG production (OR 0.1, p=0.008), bacteremia (OR 3.3, p=0.048) and presence of CMV (OR 3.3, p=0.046) showed a significant association with aGVHD 3-4. And with respect to cGVHD, the genotype -308 GG (low production) of TNF (OR 3.3, p=0.038), PB as source (OR 5.0, p=0.028), myeloablative conditioning (OR 3.3, p=0.014) and previous aGVHD 2-4 (OR 2.6, p=0.029). Although it is necessary to confirm these findings, the genotype of lower IFNG production was associated with a later engraftment and less severe aGVHD and genotypes of lower TNF production was related to a higher incidence of cGVHD contributing to the development of complications in allo-HSCT.Fil: Palau Nagore, Maria Virginia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Berro, Mariano. Universidad Austral; ArgentinaFil: Bestach, Yesica Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Rivas, M.M.. Universidad Austral; ArgentinaFil: Foncuberta, C.. Instituto Alexander Fleming; ArgentinaFil: Vitriu, A.. Instituto Alexander Fleming; ArgentinaFil: Remaggi, G.. Fundaleu; ArgentinaFil: Martínez Rolón, J.. Fundaleu; ArgentinaFil: Jaimovich, Sebastian Gaston. Fundación Favaloro; ArgentinaFil: Requejo, A.. Fundación Favaloro; ArgentinaFil: Padros, K.. Primer Centro Argentino de Inmunogenética; ArgentinaFil: Rodríguez, M.B.. Primer Centro Argentino de Inmunogenética; ArgentinaFil: Kusminsky, G.. Universidad Austral; ArgentinaFil: Larripa, Irene Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Belli, Carolina Bárbara. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentin

Fractures, Bone Mineral Density, and Final Height in Craniopharyngioma Patients with a Follow-up of 16 Years

CONTEXT: Pituitary hormonal deficiencies in patients with craniopharyngioma may impair their bone health. OBJECTIVE: To investigate bone health in patients with craniopharyngioma. DESIGN: Retrospective cross-sectional study. SETTING: Dutch and Swedish referral centers. PATIENTS: Patients with craniopharyngioma (n = 177) with available data on bone health after a median follow-up of 16 years (range, 1-62) were included (106 [60%] Dutch, 93 [53%] male, 84 [48%] childhood-onset disease). MAIN OUTCOME MEASURES: Fractures, dual X-ray absorptiometry-derived bone mineral density (BMD), and final height were evaluated. Low BMD was defined as T- or Z-score ≤-1 and very low BMD as ≤-2.5 or ≤-2.0, respectively. RESULTS: Fractures occurred in 31 patients (18%) and were more frequent in men than in women (26% vs. 8%, P = .002). Mean BMD was normal (Z-score total body 0.1 [range, -4.1 to 3.5]) but T- or Z-score ≤-1 occurred in 47 (50%) patients and T-score ≤-2.5 or Z-score ≤-2.0 in 22 (24%) patients. Men received less often treatment for low BMD than women (7% vs. 18%, P = .02). Female sex (OR 0.3, P = .004) and surgery (odds ratio [OR], 0.2; P = .01) were both independent protective factors for fractures, whereas antiepileptic medication was a risk factor (OR, 3.6; P = .03), whereas T-score ≤-2.5 or Z-score ≤-2.0 was not (OR, 2.1; P = .21). Mean final height was normal and did not differ between men and women, or adulthood and childhood-onset patients. CONCLUSIONS: Men with craniopharyngioma are at higher risk than women for fractures. In patients with craniopharyngioma, a very low BMD (T-score ≤-2.5 or Z-score ≤-2.0) seems not to be a good predictor for fracture risk

Regional climate hindcast simulations within EURO-CORDEX: evaluation of a WRF multi-physics ensemble

In the current work we present six hindcast WRF (Weather Research and Forecasting model) simulations for the EURO-CORDEX (European Coordinated Regional Climate Downscaling Experiment) domain with different configurations in microphysics, convection and radiation for the time period 1990?2008. All regional model simulations are forced by the ERA-Interim reanalysis and have the same spatial resolution (0.44°). These simulations are evaluated for surface temperature, precipitation, short- and longwave downward radiation at the surface and total cloud cover. The analysis of the WRF ensemble indicates systematic temperature and precipitation biases, which are linked to different physical mechanisms in the summer and winter seasons. Overestimation of total cloud cover and underestimation of downward shortwave radiation at the surface, mostly linked to the Grell?Devenyi convection and CAM (Community Atmosphere Model) radiation schemes, intensifies the negative bias in summer temperatures over northern Europe (max ?2.5 °C). Conversely, a strong positive bias in downward shortwave radiation in summer over central (40?60%) and southern Europe mitigates the systematic cold bias over these regions, signifying a typical case of error compensation. Maximum winter cold biases are over northeastern Europe (?2.8 °C); this location suggests that land?atmosphere rather than cloud?radiation interactions are to blame. Precipitation is overestimated in summer by all model configurations, especially the higher quantiles which are associated with summertime deep cumulus convection. The largest precipitation biases are produced by the Kain?Fritsch convection scheme over the Mediterranean. Precipitation biases in winter are lower than those for summer in all model configurations (15?30%). The results of this study indicate the importance of evaluating not only the basic climatic parameters of interest for climate change applications (temperature and precipitation), but also other components of the energy and water cycle, in order to identify the sources of systematic biases, possible compensatory or masking mechanisms and suggest pathways for model improvement.The contribution from Universidad de Cantabria was funded by the Spanish R&D programme through projects CORWES (CGL2010-22158-C02-01) and WRF4G (CGL2011-28864), co-funded by the European Regional Development Fund. M. García-Díez acknowledges financial support from the EXTREMBLES (CGL2010-21869) project

Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)

INTRODUCTION: Despite the development of new therapies for advanced prostate cancer, it remains the most common cause of cancer and the second leading cause of cancer death in men. It is critical to develop novel agents for the treatment of prostate cancer, particularly those that target aspects of androgen receptor (AR) signalling or prostate biology other than inhibition of androgen synthesis or AR binding. Neoadjuvant pharmacodynamic studies allow for a rational approach to the decisions regarding which targeted therapies should progress to phase II/III trials. CDK4/6 inhibitors have evidence of efficacy in breast cancer, and have been shown to have activity in preclinical models of hormone sensitive and castrate resistant prostate cancer. The LEEP trial aims to assess the pharmacodynamic effects of LEE011 (ribociclib), an orally bioavailable and highly selective CDK4/6 inhibitor, in men undergoing radical prostatectomy for high-risk, localised prostate cancer. METHODS AND ANALYSIS: The multicentre randomised, controlled 4:1 two-arm, phase II, open label pharmacodynamic study will recruit 47 men with high risk, localised prostate cancer who are planned to undergo radical prostatectomy. Participants who are randomised to receive the study treatment will be treated with LEE011 400 mg daily for 21 days for one cycle. The primary endpoint is the frequency of a 50% reduction in Ki-67 proliferation index from the pretreatment prostate biopsy compared to that present in prostate cancer tissue from radical prostatectomy. Secondary and tertiary endpoints include pharmacodynamic assessment of CDK4/6 cell cycle progression via E2F levels, apoptotic cell death by cleaved caspase-3, changes in serum and tumour levels of Prostate Specific Antigen (PSA), pathological regression, safety via incidence of adverse events and exploratory biomarker analysis. ETHICS AND DISSEMINATION: The protocol was approved by a central ethics review committee (St Vincent's Hospital HREC) for all participating sites (HREC/17/SVH/294). Results will be disseminated in peer-reviewed journals and at scientific conferences. DRUG SUPPLY: Novartis. PROTOCOL VERSION: 2.0, 30 May 2019 TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry (ACTRN12618000354280).Tahlia Scheinberg, James Kench, Martin Stockler, Kate L Mahon, Lucille Sebastian, Phillip Stricker, Anthony M Joshua, H Woo, Ruban Thanigasalam, Nariman Ahmadi, Margaret M Centenera, Lisa M Butler, Lisa G Horvat

MicroRNA-132/212 family enhances arteriogenesis after hindlimb ischaemia through modulation of the Ras-MAPK pathway

Arteriogenesis is a complicated process induced by increased local shear-and radial wall-stress, leading to an increase in arterial diameter. This process is enhanced by growth factors secreted by both inflammatory and endothelial cells in response to physical stress. Although therapeutic promotion of arteriogenesis is of great interest for ischaemic diseases, little is known about the modulation of the signalling cascades via microRNAs. We observed that miR-132/212 expression was significantly upregulated after occlusion of the femoral artery. miR-132/212 knockout (KO) mice display a slower perfusion recovery after hind-limb ischaemia compared to wildtype (WT) mice. Immunohistochemical analysis demonstrates a clear trend towards smaller collateral arteries in KO mice. Although Ex vivo aortic ring assays score similar number of branches in miR-132/212 KO mice compared to WT, it can be stimulated with exogenous miR-132, a dominant member of the miR-132/212 family. Moreover, in in vitro pericyte-endothelial co-culture cell assays, overexpression of miR-132 and mir-212 in endothelial cells results in enhanced vascularization, as shown by an increase in tubular structures and junctions. Our results suggested that miR-132/212 may exert their effects by enhancing the Ras-Mitogen-activated protein kinases MAPK signalling pathway through direct inhibition of Rasa1, and Spred1. The miR-132/212 cluster promotes arteriogenesis by modulating Ras-MAPK signalling via direct targeting of its inhibitors Rasa1 and Spred1

Magic, Emotion and Practical Metabolism:Affective Praxis in Sartre and Collingwood

This article develops a new way of understanding the integration of emotions in practical life and the practical appraisal of emotions, drawing on insights from both J-P. Sartre and R. G. Collingwood. I develop a concept of ‘practical metabolism’ and show that emotions need to be understood not only as transformations from determinate to indeterminate practical intuitions, but also as transformations in the reverse direction. Firstly, I provide a new conception of the dynamic phenomenal structure of the emotions that can resolve significant tensions in the Sartre’s theory. Secondly, I develop that theory to shed light on the diverse socially mediated roles of emotions in practical life by drawing on Collingwood’s philosophy of magic. Thirdly, I deploy the notion of practical metabolism to address the appraisal of emotions, setting out a framework for understanding the various ways in which emotional expression is subject to structural breakdown

Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project

Introduction: Preoperative treatment and adequate surgery increase local control in rectal cancer. However, modalities and indications for neoadjuvant treatment may be controversial. Aim of this study was to assess the trends of preoperative treatment and outcomes in patients with rectal cancer included in the Rectal Cancer Registry of the Spanish Associations of Surgeons. Method: This is a STROBE-compliant retrospective analysis of a prospective database. All patients operated on with curative intention included in the Rectal Cancer Registry were included. Analyses were performed to compare the use of neoadjuvant/adjuvant treatment in three timeframes: I)2006–2009; II)2010–2013; III)2014–2017. Survival analyses were run for 3-year survival in timeframes I-II. Results: Out of 14, 391 patients, 8871 (61.6%) received neoadjuvant treatment. Long-course chemo/radiotherapy was the most used approach (79.9%), followed by short-course radiotherapy ± chemotherapy (7.6%). The use of neoadjuvant treatment for cancer of the upper third (15-11 cm) increased over time (31.5%vs 34.5%vs 38.6%, p = 0.0018). The complete regression rate slightly increased over time (15.6% vs 16% vs 18.5%; p = 0.0093); the proportion of patients with involved circumferential resection margins (CRM) went down from 8.2% to 7.3%and 5.5% (p = 0.0004). Neoadjuvant treatment significantly decreased positive CRM in lower third tumors (OR 0.71, 0.59–0.87, Cochrane-Mantel-Haenszel P = 0.0008). Most ypN0 patients also received adjuvant therapy. In MR-defined stage III patients, preoperative treatment was associated with significantly longer local-recurrence-free survival (p < 0.0001), and cancer-specific survival (p < 0.0001). The survival benefit was smaller in upper third cancers. Conclusion: There was an increasing trend and a potential overuse of neoadjuvant treatment in cancer of the upper rectum. Most ypN0 patients received postoperative treatment. Involvement of CRM in lower third tumors was reduced after neoadjuvant treatment. Stage III and MRcN + benefited the most